| Execution period | June 2026 to May 2027 |
|---|
BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,644.80
- Market cap
- ₹95,530 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.2×Sector 46.1×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Board Meeting Date
Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.
Aurobindo Pharma Other Announcement
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma Business Update
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma Acquisition
Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.
Aurobindo Pharma Acquisition Worth ₹146.4 Cr
Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.
- Value
- ₹146.4 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
- Value
- ₹33.80 Cr
Other management change announcements
All →Transgene Biotek Management Change
Transgene Biotek's statutory auditors Eswara Rao & Co. resigned effective 28 October 2026 citing pre-occupation. The company will appoint new auditors per applicable regulations.
Mobavenue AI Tech Management Change
Mobavenue AI Tech appointed Vikram Sheth as Chief of Corporate Development and Investor Relations. He will lead fundraising, acquisitions and investor relations.
Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.
GMR Airports Management Change
GMR Airports appointed Sanjeev Gupta as Executive Director (Deputy CEO) effective 29 October 2026. Non-Executive Director Alexis Riols resigned effective 28 October 2026.
Raymond Realty Management Change
Raymond Realty said joint statutory auditor Chaturvedi & Shah LLP resigned on 28 October 2026 after a dispute over audit fee revision. Walker Chandiok & Co LLP continues as the other statutory auditor.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.